Core Viewpoint - The company is committed to deepening its presence in the consumer electronics sector by focusing on high-end, high-value-added product positioning through technological innovation and global capacity layout [1] Group 1: Product Strategy - The company aims to expand the depth and breadth of cooperation with key clients by aligning with customer needs and enriching its product structure [1] - The development of more adaptable product solutions is a priority for the company [1] Group 2: Industry Collaboration - The company plans to enhance collaborative innovation with upstream and downstream enterprises to build an integrated industrial ecosystem encompassing "materials - devices - applications" [1] - Joint research and resource sharing will be utilized to strengthen the overall competitiveness of the industry chain [1] Group 3: Market Adaptation and R&D Investment - The company will actively expand into emerging fields in response to market demand changes and increase specialized R&D investment [1] - A cross-disciplinary R&D team will be established, collaborating with universities and research institutions to accelerate the transformation of technological achievements [1] - The goal is to diversify the business structure and inject new momentum for long-term sustainable development [1]

Core Viewpoint - Xinhua Pharmaceutical has received approval from the National Medical Products Administration for the registration of glucosamine sulfate capsule, which is classified as a Class 4 chemical drug and a Class A non-prescription drug, aimed at treating primary and secondary osteoarthritis [1] Group 1 - The glucosamine sulfate capsule is available in specifications of 0.25g or 0.314g [1] - The drug has been included in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2025) as a Category B product [1]

证券日报网讯 2月9日，福莱蒽特在互动平台回答投资者提问时表示，公司通过参股钛深科技、设立合 资公司双曲线智能布局柔性传感领域，相关方已形成对应专利组合，公司同步推进技术与知识产权协 同，具体专利信息以相关方披露为准。目前柔性传感业务以研发中试为主，产能规划将结合市场需求、 技术成熟度动态调整，重大产能建设计划将及时履行信息披露义务。公司目前暂无该领域扩产及引入战 投的应披露计划，后续如有相关安排，将严格履行信息披露义务。 （编辑 丛可心） ...

Core Viewpoint - The sales of Anjiahin® are expected to decline significantly by 2025 due to several factors, including medical insurance cost control and substantial price reductions initiated by the company in response to national healthcare policies [1] Group 1: Sales and Market Impact - The decline in Anjiahin® sales is primarily influenced by the reduction in patient usage resulting from medical insurance cost control measures [1] - Starting from the third quarter of 2025, Anjiahin® will undergo significant price cuts to align with the national healthcare bureau's initiatives, aiming to make the medication more accessible to patients [1] Group 2: Treatment Guidelines and Patient Care - The revised "Chinese Guidelines for Hemophilia Treatment (2025 Edition)" has redefined treatment approaches for coagulation disorders, shifting from traditional preventive treatment to regular replacement therapy and from on-demand treatment to temporary replacement therapy [1] - The medical community is emphasizing the importance of preventive treatment, and the company hopes that adult patients will receive similar protections as pediatric patients [1] - The company anticipates that the recombinant factor VIII will receive equal treatment as blood-derived factor VIII in the future [1]

（编辑 姚尧） 证券日报网讯 2月9日，红日药业在互动平台回答投资者提问时表示，公司高度重视投资者的诉求，公 司的信息披露工作是基于公平信息披露原则的合规操作。针对所涉事项目若尚未达到法定信息披露标 准，也未对公司生产经营，财务状况产生重大影响，公司无法在互动易平台进行答复。若在平台对未达 披露标准的事项进行证实或辟谣，将造成信息不对称，损害中小投资者的公平知情权，违背信息披露的 核心原则。公司始终对相关事项进展保持密切跟踪，若后续事项达到《上市公司信息披露管理办法》规 定的重大事项披露标准，将第一时间通过巨潮资讯网等指定信息披露渠道发布公告，确保所有投资者同 步获取信息。公司将坚守不断提升公司经营与创新能力的原则，以实际行动提升公司可持续盈利能力， 切实维护全体股东的合法权益。公司信息请以巨潮资讯网及深圳证券交易所发布的公告为准。 ...

Group 1 - The core viewpoint of the article highlights that the company, Funeng Technology, has secured multiple customer projects for its SPS products, including partnerships with major automotive manufacturers such as GAC, Geely, Jiangling, SANY Heavy Truck, and FAW Liberation [1] - The company reports that it has a sufficient backlog of orders and that the production capacity utilization rates at its Ganzhou and Guangzhou SPS bases are steadily increasing [1]

Core Viewpoint - The company is focusing on enhancing its product series and expanding into new application areas by collaborating with research institutions and responding to market demands [1] Group 1 - The company aims to achieve breakthroughs in fields such as life sciences, semiconductors, rare and precious metal separation and extraction, and nuclear-grade resins [1] - The company emphasizes its commitment to comply with relevant laws and regulations regarding information disclosure [1] - The company will announce any significant matters that meet disclosure standards in a timely manner [1]

（编辑 袁冠琳） 证券日报网讯 2月9日，立霸股份发布公告称，公司于近日收到由江苏省科学技术厅、江苏省财政厅、 国家税务总局江苏省税务局联合颁发的《高新技术企业证书》，证书编号为GR202532009078，发证时 间为2025年12月19日，有效期三年。 ...

Group 1 - The company, Green Eco, is considering the necessity and feasibility of purchasing directors and officers liability insurance based on industry practices and its own operational status [1] - The company emphasizes its commitment to strictly adhere to laws and regulations while safeguarding the legitimate rights and interests of all investors [1]

证券日报网讯 2月9日，吴通控股在互动平台回答投资者提问时表示，目前公司经营情况正常，具体经 营数据等内容敬请关注公司定期报告等相关公告。公司现将尚未使用的募集资金留存于募集资金专户， 并在保证不影响募投项目建设及确保资金安全的情况下，使用审议额度内的闲置募集资金进行现金管 理。后续如有相关事项达到披露标准，公司将及时履行信息披露义务。敬请投资者理性投资，注意风 险。 （编辑 楚丽君） ...